The Royal Asia Enterprise International Limited (Royal Asia), a Hong Kong-based company, is spearheading the efforts to release the Fabunan Antiviral Injection (FAI) drug (2 US patent) to the international market in Southeast Asia.
Mario Marcos, the CEO and President of The Royal Asia Enterprise International Limited, announced that business negotiations are proceeding with several international parties interested in the capability of the FAI drug with regards its powerful anti-viral and anti-inflammatory capability as a remedy against enveloped viruses like Dengue, Influenza, HIV, Ebola and the new Coronavirus which is now sweeping the world in a pandemic proportion.

Mario Marcos says that the FAI drug was patented by Dr. Ruben Garcia Fabunan in the United States 35 years ago.  They go on to say that after he came back to the Philippines, he further developed and proved the effectiveness of the drug in clinical practice with the assistance of his younger sibling doctors Oscar, Willie, and Roman Jr.

To help the people understand the vital role that the FAI drug plays in the fight against the coronavirus, they first sought to explain the two major types of viruses which include enveloped and non-enveloped viruses.

The company explains that enveloped viruses are types of viruses that are encased with a lipoprotein membrane such as HIV, Influenza, Dengue, Ebola, and Coronavirus which are all human pathogens. They further add that the lipid portion of the membrane envelope is relatively sensitive and is susceptible to destruction by several physical and chemical agents thus killing the virus.

The health experts go on to explain that non-enveloped or “naked” viruses’, like the rotavirus and poliovirus, are also pathogens but are devoid of a lipid membrane and characterized by higher resistance to most disinfectants and other environmental stresses like drying out or heat.

They give the example of how alcohol is effective at killing enveloped viruses, including the coronavirus, but is less effective at killing the non-enveloped rotavirus found in the kitchen or toilets.

According to SMART Foundation, the success in a British laboratory test of dexamethasone, a cheap steroid, in considerably reducing death rates in hospitalized patients puts the FAI in a very desirable pharmaceutical position. The CEO, Mario Marcos says that Dexamethasone is one of the two main ingredients of the FAI drug and that effective treatment for serious COVID-19 patients is crucial especially with the increasing death rates caused by the Coronavirus disease all over the world.

In addition, these laboratory results have made the Japanese health ministry to approve dexamethasone as a second treatment of Covid-19 in addition to Remdesevir. The experts advise that Dexamethasone is a less expensive drug with a price range of US$5.53 to US$18.58 per 25 ml while treatment using Remdesivir can cost around S$2,340 over five days.

Experts are confident in Dexamethasone as a lifesaving drug for COVID-19, terming it a breakthrough in the coronavirus pandemic.

The CEO concluded by saying that the results announced last June by the UK research group gave a scientific basis for the Philippine-developed FAI formulation which combines dexamethasone with the anesthetic procaine, and that it put the Fabunan Antiviral Injection in a very strong position as an effective treatment for COVID-19 patients.

About the Company

Royal Asia Enterprise International Limited is a company that engages in sourcing, trading, marketing, and distribution worldwide of apparel, medicines, and other general merchandise.

For more information, contact them today.

Media Contact
Company Name: The Royal Asia Enterprise International Limited
Contact Person: Mario Marcos
Email: Send Email
Phone: +6281319171065
Address:Sui Ying Industrial Bldg., Phase One Flat 5, 8/F No. 41 Lok Shan Road To Kwa Wan
City: Kowloon
Country: HongKong
Website: rebrand.ly/royalasia